Palantir Expands Longstanding CDC Partnership for Disease Monitoring and Response

Palantir Technologies (NYSE:PLTR) has expanded its partnership with the CDC to enhance outbreak response and disease surveillance via the DCIPHER program.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

partnership

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/15/2022 - 06:59 AM

Centers for Disease Control and Prevention Continues Critical Work to Modernize Data Management

DENVER--(BUSINESS WIRE)-- Palantir Technologies Inc. (NYSE:PLTR) today announced an extension and expansion of its work with the U.S. Centers for Disease Control and Prevention (CDC) through the outbreak response and disease surveillance solution for the Data Collation and Integration for Public Health Event Response (DCIPHER) Program.

Over a decade ago, Palantir and the CDC initially partnered to support the agency’s efforts to manage foodborne outbreaks and the partnership grew to include countering Ebola and the management of anthrax and bacterial special pathogens. Palantir’s work on the DCIPHER Program utilizes the Palantir Foundry platform to support the time-sensitive data integration, management, and analysis that widespread events require.

Since its first project in 2010, Palantir and the CDC’s DCIPHER Program have increased their efforts together to include additional food-borne pathogens, respiratory pathogens, genomics-specific data challenges, as well as facilitating expanded collaboration between the CDC and state, tribal, local, and territorial (STLT) partners. These initiatives are separate and distinct from Palantir’s COVID-19 response work with U.S. federal health agencies.

“We are honored to continue and expand our long-standing partnership with CDC in support of public health surveillance and outbreak response,” said Dr. William Kassler, Chief Medical Officer for USG at Palantir. “Beyond COVID, by incorporating innovative genomic workflows into traditional public health surveillance, CDC is building upon its foundational investments in a modernized technology infrastructure.”

Select examples of programs currently using DCIPHER include the System for Enteric Disease Response, Investigation, the National Center for Immunization and Respiratory Diseases (NCIRD), and Coordination (SEDRIC) and the National Wastewater Surveillance System (NWSS) within the CDC’s Division of Foodborne, Waterborne, and Environmental Diseases.

Leveraging Palantir’s Foundry platform, including reusable data frameworks and workflows, DCIPHER has enabled workgroups across CDC to rapidly integrate data, carry out analysis, and configure operational workflows for public health needs. The result has been highly synchronized surveillance and coordinated operations and response.

Palantir Foundry enables data-driven decision-making by integrating data from siloed data sources and enabling granular access across various organizations. It is used by several federal health agencies, including the National Institutes of Health, the Department of Health and Human Services, and the Food and Drug Administration, and was also used by several military branches to mitigate the impact of the COVID-19 pandemic.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.